Gynecological Malignancy
1 clinical trials · Condition
◉ Watch Gynecological Malignancy
| Record | Firm | Date |
|---|---|---|
| A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies (NCT04965519) | RemeGen Co., Ltd. | 2021-12-21 |
Track Gynecological Malignancy automatically
Every clearance here is in the API, with alerts when new ones post.